药物再利用筛选发现羟基脲可靶向从头DNA合成使胶质母细胞瘤对替莫唑胺敏感且与分子亚型无关
该研究在替莫唑胺耐药的胶质母细胞瘤细胞系及原代培养中开展药物再利用筛选,发现羟基脲与替莫唑胺在体外和体内均协同作用,且不依赖于MGMT启动子甲基化状态、亚型或干性。羟基脲通过抑制核糖核苷酸还原酶M2亚基作用于细胞周期S期,RNA干扰敲低该酶或其他化学抑制剂可产生类似效果。结论为羟基脲联合替莫唑胺用于胶质母细胞瘤辅助治疗具有临床前疗效。
要点
- 药物再利用筛选发现羟基脲与替莫唑胺在胶质母细胞瘤中协同。
- 协同作用不依赖MGMT启动子甲基化状态、亚型或干性。
- 羟基脲通过抑制核糖核苷酸还原酶M2亚基作用于S期。
核心结论
- 临床前研究显示羟基脲联合替莫唑胺用于胶质母细胞瘤辅助治疗具有疗效。
研究设计与样本
- 在替莫唑胺耐药的胶质母细胞瘤细胞系及新诊断胶质母细胞瘤原代培养中开展药物再利用筛选,涵盖不同MGMT启动子甲基化状态、表型/基因型背景和亚型,并通过成球实验、细胞迁移实验及定量侵袭性原位体内模型验证。
主要发现
- 羟基脲与替莫唑胺在培养的胶质母细胞瘤细胞及体内均协同,且不依赖MGMT启动子甲基化状态、亚型和/或干性。
- 羟基脲通过抑制核糖核苷酸还原酶M2亚基特异性作用于细胞周期S期。
- RNA干扰敲低该酶及其他已知化学抑制剂与替莫唑胺联用在培养和体内均产生与羟基脲类似的效果。
临床怎么用
- 作者认为羟基脲联合替莫唑胺用于胶质母细胞瘤辅助治疗具有临床前疗效,该联合获益具有直接临床意义。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Glioblastoma (GBM) is the most common and most aggressive primary malignant brain tumor. Standard-of-care treatment involves maximal surgical resection of the tumor followed by radiation and chemotherapy (temozolomide [TMZ]). The 5-year survival rate of patients with GBM is <10%, a colossal failure that has been partially attributed to intrinsic and/or acquired resistance to TMZ through O6-methylguanine DNA methyltransferase (MGMT) promoter methylation status in the tumor. METHODS: A drug screening aimed at evaluating the potential recycling and repurposing of known drugs was conducted in TMZ-resistant GBM cell lines and primary cultures of newly diagnosed GBM with different MGMT promoter methylation status, phenotypic/genotypic background and subtype, and validated with sphere formation, cell migration assays, and quantitative invasive orthotopic in vivo models. RESULTS: We identified hydroxyurea (HU) to synergize with TMZ in GBM cells in culture and in vivo, irrespective of MGMT promoter methylation status, subtype, and/or stemness. HU acts specifically on the S-phase of the cell cycle by inhibiting the M2 unit of enzyme ribonucleotide reductase. Knockdown of this enzyme using RNA interference and other known chemical inhibitors exerted a similar effect to HU in combination with TMZ both in culture and in vivo. CONCLUSIONS: We demonstrate preclinical efficacy of repurposing hydroxyurea in combination with TMZ for adjuvant GBM therapy. This combination benefit is of direct clinical interest given the extensive use of TMZ and the associated problems with TMZ-related resistance and treatment failure.
引用
- Teng J, Hejazi S, Hiddingh L, et al. Recycling drug screen repurposes hydroxyurea as a sensitizer of glioblastomas to temozolomide targeting de novo DNA synthesis, irrespective of molecular subtype. Neuro Oncol. 2018. PMID: 29099956. doi:10.1093/neuonc/nox198
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。